Feature | January 13, 2010

January 13, 2010 – Research validates the efficacy of the recent reclassification of the T category in the International Association for the Study of Lung Cancer’s (IASLC) "Staging Manual in Thoracic Oncology" released in the January 2010 issue of the Journal of Thoracic Oncology.

In the sixth edition of the tumor, node and metastatis (TNM) staging system, there were no changes. Thus, the change in the seventh edition is significant as it is the first revision of TMN classification in lung cancer for 12 years, and represents the most drastic change there has been in the past 30 years.

The medical records of 1,393 patients with non-small cell lung cancer who underwent complete resection were thoroughly reviewed for pathologic findings and survival. The stage of all the patients was pathologically defined according to the present international staging system, previously revised in 1997. This study examined the relationship between the cut-off points of the tumor size for the new T category and the pathologic invasiveness

The TNM staging system is useful for both the clinical assessment of tumor progression and the determination of treatment plan, such as surgery, chemotherapy and radiation. In the forthcoming TNM classification, a revision with respect to lung cancer has been proposed by the International Association for the Study of Lung Cancer. The major revision is the T category, which makes an especially strict division by detailed cut points of tumor size (e.g., 2-, 3-, 5- and 7-cm). The proposed T revision has been determined and validated based on the overall survival date from a large international database.

The lead study author, Tokujiro Yano, M.D., called the new T classification, which is based mainly on the tumor size, “appropriate for the pathologic findings of the primary tumor.” The significant differences were observed among newly revised T subsets in at least one incidence of pathologic invasiveness, including lymphatic, vascular, or pleural invasion.

Past chair and author of the IASLC’s staging guide, Peter Goldstraw, added that IASLC will play a central role in the formation of future classification of TMN.

For more information: www.iaslcpubs.org/IASLC-Manual-Thoracic-print.html


Related Content

News | FDA

March 24, 2026 — MARS Bioimaging, a New Zealand–headquartered medical device company, has received U.S. Food and Drug ...

Time March 25, 2026
arrow
News | FDA

March 20, 2026 — Siemens Healthineers recently announced its Varian TrueBeam radiotherapy systems, which include ...

Time March 24, 2026
arrow
News | Radiology Imaging

March 23, 2026 — Samsung Medison hsa announced that its U.S. medical imaging businesses, previously operating as ...

Time March 23, 2026
arrow
News | Radiology Education

March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...

Time March 17, 2026
arrow
News | Breast Imaging

March 10, 2026 — QT Imaging Holdings has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an ...

Time March 13, 2026
arrow
News | Lung Imaging

March 11, 2026 — Noah Medical has announced the publication of the MATCH 2 study in the international, peer-reviewed ...

Time March 12, 2026
arrow
News | Computed Tomography (CT)

March 5, 2026 — At ECR 2026, Royal Philips introduced Rembra, its next-generation radiology CT system designed for the ...

Time March 09, 2026
arrow
Feature | Artificial Intelligence | Kyle Hardner

Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...

Time March 09, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | Ultrasound Imaging

March 2, 2026 — Esaote Group will officially launch the new MyLab E85 and MyLab C30 GTS Edition ultrasound systems at ...

Time March 02, 2026
arrow
Subscribe Now